Shorter TB course could be Game-Changer for HIV patients
NCT ID NCT07608172
First seen May 29, 2026
Summary
This study tests whether a shorter, 5-month combination of TB drugs works as well as the standard 6-month treatment for people with both HIV and drug-susceptible tuberculosis. It involves 148 participants with very weak immune systems (CD4 count under 100). The goal is to see if the shorter regimen can effectively treat TB while reducing side effects and treatment burden.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
isoniazid, rifapentine, moxifloxacin, pyrazinamide
What this could lead to
If successful, this could offer a shorter, more convenient treatment option for tuberculosis in people with advanced HIV, potentially improving adherence and outcomes.
What could go wrong
This is a relatively small, early-stage validation study. The shorter regimen may not be as effective or safe as the standard longer course, and results may not apply to all patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.